PHARMING GROUP NV (PHGN.DE) Fundamental Analysis & Valuation

FRA:PHGN • NL0010391025

Current stock price

1.36 EUR
+0.03 (+2.33%)
Last:

This PHGN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHGN.DE Profitability Analysis

1.1 Basic Checks

  • In the past year PHGN has reported negative net income.
  • PHGN had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PHGN reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: PHGN reported negative operating cash flow in multiple years.
PHGN.DE Yearly Net Income VS EBIT VS OCF VS FCFPHGN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.56%, PHGN is in the better half of the industry, outperforming 67.09% of the companies in the same industry.
  • PHGN's Return On Equity of 1.02% is fine compared to the rest of the industry. PHGN outperforms 70.89% of its industry peers.
  • PHGN has a better Return On Invested Capital (5.89%) than 77.22% of its industry peers.
Industry RankSector Rank
ROA 0.56%
ROE 1.02%
ROIC 5.89%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
PHGN.DE Yearly ROA, ROE, ROICPHGN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.75%, PHGN is in the better half of the industry, outperforming 68.35% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PHGN has declined.
  • PHGN's Operating Margin of 8.54% is fine compared to the rest of the industry. PHGN outperforms 78.48% of its industry peers.
  • PHGN's Operating Margin has declined in the last couple of years.
  • PHGN has a Gross Margin of 87.91%. This is in the better half of the industry: PHGN outperforms 79.75% of its industry peers.
  • PHGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.54%
PM (TTM) 0.75%
GM 87.91%
OM growth 3Y19.35%
OM growth 5Y-24.92%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
PHGN.DE Yearly Profit, Operating, Gross MarginsPHGN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PHGN.DE Health Analysis

2.1 Basic Checks

  • PHGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for PHGN has been increased compared to 1 year ago.
  • Compared to 5 years ago, PHGN has more shares outstanding
  • Compared to 1 year ago, PHGN has an improved debt to assets ratio.
PHGN.DE Yearly Shares OutstandingPHGN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
PHGN.DE Yearly Total Debt VS Total AssetsPHGN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • PHGN has an Altman-Z score of 1.02. This is a bad value and indicates that PHGN is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of PHGN (1.02) is comparable to the rest of the industry.
  • PHGN has a debt to FCF ratio of 2.15. This is a good value and a sign of high solvency as PHGN would need 2.15 years to pay back of all of its debts.
  • The Debt to FCF ratio of PHGN (2.15) is better than 88.61% of its industry peers.
  • A Debt/Equity ratio of 0.39 indicates that PHGN is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.39, PHGN perfoms like the industry average, outperforming 59.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Altman-Z 1.02
ROIC/WACC1.01
WACC5.85%
PHGN.DE Yearly LT Debt VS Equity VS FCFPHGN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • PHGN has a Current Ratio of 2.59. This indicates that PHGN is financially healthy and has no problem in meeting its short term obligations.
  • PHGN has a Current ratio (2.59) which is comparable to the rest of the industry.
  • A Quick Ratio of 2.03 indicates that PHGN has no problem at all paying its short term obligations.
  • PHGN's Quick ratio of 2.03 is in line compared to the rest of the industry. PHGN outperforms 45.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.03
PHGN.DE Yearly Current Assets VS Current LiabilitesPHGN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. PHGN.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 111.11% over the past year.
  • PHGN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.41% yearly.
  • PHGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.55%.
  • The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)111.11%
EPS 3Y-40.82%
EPS 5Y-48.41%
EPS Q2Q%60%
Revenue 1Y (TTM)26.55%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%

3.2 Future

  • PHGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 157.07% yearly.
  • The Revenue is expected to grow by 12.57% on average over the next years. This is quite good.
EPS Next Y1877.6%
EPS Next 2Y329.38%
EPS Next 3Y213.1%
EPS Next 5Y157.07%
Revenue Next Year8.86%
Revenue Next 2Y5.74%
Revenue Next 3Y2.04%
Revenue Next 5Y12.57%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHGN.DE Yearly Revenue VS EstimatesPHGN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHGN.DE Yearly EPS VS EstimatesPHGN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. PHGN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Forward Earnings ratio of 39.73 indicates a quite expensive valuation of PHGN.
  • Based on the Price/Forward Earnings ratio, PHGN is valued a bit cheaper than 75.95% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.42, PHGN is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 39.73
PHGN.DE Price Earnings VS Forward Price EarningsPHGN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHGN is valued cheaper than 98.73% of the companies in the same industry.
  • 100.00% of the companies in the same industry are more expensive than PHGN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.03
EV/EBITDA 0.29
PHGN.DE Per share dataPHGN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PHGN's earnings are expected to grow with 213.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y329.38%
EPS Next 3Y213.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHGN.DE Dividend Analysis

5.1 Amount

  • No dividends for PHGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHGN.DE Fundamentals: All Metrics, Ratios and Statistics

PHARMING GROUP NV

FRA:PHGN (3/20/2026, 7:00:00 PM)

1.36

+0.03 (+2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners24.69%
Inst Owner ChangeN/A
Ins Owners1.35%
Ins Owner ChangeN/A
Market Cap94.75M
Revenue(TTM)376.10M
Net Income(TTM)2.82M
Analysts88.57
Price Target2.19 (61.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)532.06%
Min EPS beat(2)-6.76%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)286.26%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)81.54%
EPS beat(12)5
Avg EPS beat(12)48.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.68%
Max Revenue beat(2)1.11%
Revenue beat(4)3
Avg Revenue beat(4)5.37%
Min Revenue beat(4)-1.68%
Max Revenue beat(4)13.37%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)7
Avg Revenue beat(12)0.29%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.49%
PT rev (3m)9.14%
EPS NQ rev (1m)-95%
EPS NQ rev (3m)-95%
EPS NY rev (1m)51.18%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)4.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 39.73
P/S 0.29
P/FCF 2.03
P/OCF 2
P/B 0.4
P/tB 0.77
EV/EBITDA 0.29
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY2.52%
FCF(TTM)0.67
FCFY49.28%
OCF(TTM)0.68
OCFY49.97%
SpS4.67
BVpS3.44
TBVpS1.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.56%
ROE 1.02%
ROCE 8.36%
ROIC 5.89%
ROICexc 11.03%
ROICexgc 32.53%
OM 8.54%
PM (TTM) 0.75%
GM 87.91%
FCFM 14.35%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y55.24%
ROICexgc growth 5Y-23.76%
ROICexc growth 3Y34.03%
ROICexc growth 5Y-22.4%
OM growth 3Y19.35%
OM growth 5Y-24.92%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Debt/EBITDA 2.47
Cap/Depr 6.73%
Cap/Sales 0.2%
Interest Coverage 5.18
Cash Conversion 126.22%
Profit Quality 1911.19%
Current Ratio 2.59
Quick Ratio 2.03
Altman-Z 1.02
F-Score6
WACC5.85%
ROIC/WACC1.01
Cap/Depr(3y)6.96%
Cap/Depr(5y)24.22%
Cap/Sales(3y)0.36%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3Y-40.82%
EPS 5Y-48.41%
EPS Q2Q%60%
EPS Next Y1877.6%
EPS Next 2Y329.38%
EPS Next 3Y213.1%
EPS Next 5Y157.07%
Revenue 1Y (TTM)26.55%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%
Revenue Next Year8.86%
Revenue Next 2Y5.74%
Revenue Next 3Y2.04%
Revenue Next 5Y12.57%
EBIT growth 1Y472.59%
EBIT growth 3Y45.97%
EBIT growth 5Y-15.82%
EBIT Next Year4.45%
EBIT Next 3Y48.37%
EBIT Next 5Y57.73%
FCF growth 1Y2182.32%
FCF growth 3Y38.11%
FCF growth 5Y-4.61%
OCF growth 1Y3147.8%
OCF growth 3Y34.55%
OCF growth 5Y-8.14%

PHARMING GROUP NV / PHGN.DE Fundamental Analysis FAQ

What is the fundamental rating for PHGN stock?

ChartMill assigns a fundamental rating of 5 / 10 to PHGN.DE.


Can you provide the valuation status for PHARMING GROUP NV?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHGN.DE). This can be considered as Fairly Valued.


What is the profitability of PHGN stock?

PHARMING GROUP NV (PHGN.DE) has a profitability rating of 4 / 10.


What is the earnings growth outlook for PHARMING GROUP NV?

The Earnings per Share (EPS) of PHARMING GROUP NV (PHGN.DE) is expected to grow by 1877.6% in the next year.